key: cord-1045092-g2gys2hw authors: Çağlayan, Derya; Süner, Ahmet F.; Şiyve, Neslişah; Güzel, Irmak; Irmak, Çağlar; Işik, Elif; Appak, Özgür; Çelik, Muammer; Öztürk, Gamze; Alp Çavuş, Sema; Ergör, Gül; Sayiner, Arzu; Ergör, Alp; Demiral, Yücel; Kiliç, Bülent title: An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey date: 2022-02-03 journal: J Med Virol DOI: 10.1002/jmv.27620 sha: 64fa818bcd2428cbeb5f0ae4ede0c01a814b2866 doc_id: 1045092 cord_uid: g2gys2hw Limited data are available on the short‐ to midterm levels of antibodies to the CoronaVac vaccine and quantitative change in humoral response after homologous or heterologous booster doses. In this prospective cohort study, we evaluated the anti‐receptor‐binding domain (RBD) immunoglobulin G (IgG) levels after two doses of CoronaVac and heterologous/homologous booster administration among healthcare workers in a university hospital in Turkey. Quantitative anti‐RBD IgG antibody levels were measured at first and fourth months in 560 healthcare workers who had completed two doses of CoronaVac vaccine, and within 2 months after the third dose of CoronaVac or BNT162b2. Participants were asked to complete a questionnaire during the first blood draw. The seropositivity rate was 98.9% and 89.1%, and the median antibody level was 469.2 AU/ml and 166.5 AU/ml at first and fourth month, respectively. In the fourth month, a mean reduction of 61.4% ± 20% in antibody levels was observed in 79.8% of the participants. The presence of chronic disease (odds ratio [OR]: 1.76, 95% confidence interval [CI]: 1.15–2.69) and being in the 36–50 age group (OR: 2.11, 95% CI: 1.39–3.19) were identified as independent predictors for low antibody response. The antibody level increased 104.8‐fold (median: 17 609.4 vs. 168 AU/ml) and 8.7‐fold (median: 1237.9 vs. 141.4 AU/ml) in the participants who received BNT162b2 and CoronaVac, respectively. During the follow‐up, 25 healthcare workers (4.5%) were infected with severe acute respiratory syndrome coronavirus 2. Considering the waning immunity and circulating variants, a single booster dose of messenger RNA vaccine seems reasonable after the inactivated vaccine especially in risk groups. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which emerged in December 2019, affected the whole world and caused over 266 million cases and 5 million deaths as of December 9, 2021. 1 Vaccines using different platforms were developed to control the pandemic, and emergency use licenses were granted. CoronaVac 600 SU/0.5 ml (Sinovac Research & Development Co., Ltd.) is an inactivated whole virus vaccine and is administered in two doses with 14 or 28 days apart. Turkey was one of the countries where Phase 3 studies of this vaccine were conducted. 2 While the study was ongoing, emergency use approval was given by the Turkish Medical Drugs and Devices Agency on January 13, 2021, considering the rapidly increasing number of cases and deaths. In accordance with international recommendations, vaccination of healthcare workers and high-risk groups started first with Turkey becoming one of the few countries that used CoronaVac in mass vaccination after it was produced. Neutralizing antibody levels are highly predictive of immune protection from symptomatic coronavirus disease 2019 (COVID- 19) after vaccination, 3 The immune response to a vaccine is associated with several factors. 6 Individuals with immunocompromised and/or chronic disease show a reduced antibody response to vaccines and have a high risk of developing severe COVID-19 even if vaccinated. 7, 8 Therefore, evaluation of antibody response may be especially important in determining the need for a booster dose in people with comorbidities. Recently, booster dosing has been introduced in some countries because of waning protection against infection/disease over time, reduced protection against variants, and inadequate protection with primary series for risk groups. 9, 10 The U.S. Food and Drug Administration authorized booster doses of the BNT162b2 vaccine to be administered at least 6 months after completion of the primary series for certain populations. 11 At the start of the study, data on efficacy were not available as the Coronavac vaccine was newly introduced. The Occupational Health and Safety Unit (OHSU) records of the hospital were examined, and the incidence of COVID-19 in healthcare workers (n: 3538) in the prevaccine period was determined as 15%, based on the minimum 50% protective limit determined by the World Health Organization for vaccine effectiveness (the disease incidence was calculated as 7.5% in vaccinated people). The sample size was determined as 560 (Openepi, cohort sample size) with a 95% confidence level and 80% power. Systematic sampling was carried out from the vaccinated employee lists for sample selection. Participants were informed and written consent was obtained. Blood samples were taken in the first and fouth months following the administration of the second dose (between January 14 and January 20, 2021) of CoronaVac. Data on sociodemographic characteristics and factors that may affect vaccine response (including the presence of chronic disease, immunosuppressive-modulatory therapy, height-weight [body mass index, BMI: underweight: <18.5, normal weight: 18.5-24.9, overweight: 25-29.9, and obesity: >30], smoking, influenza, and pneumococcal vaccination in the last 6 months) were collected with a questionnaire at the first blood collection. The questionnaire was piloted and revised before being The outcome variable of the study was quantitative antibody level. Covariates were sociodemographic characteristics of the participants, namely BMI, underlying chronic diseases, immunosuppressivemodulatory treatment status, smoking, and vaccination with other non-COVID-19 vaccines (influenza and pneumococcus). Since the protective antibody level is not yet known, the value of the low anti-RBD IgG sample (45 BAU/ml) of the "First WHO International Reference Panel for anti-SARS-CoV-2 immunoglobulin (NIBSC code: 20/268)," is accepted as the threshold value for low antibody level for this study. 12 Therefore, 315 AU/ml was chosen as the cutoff level for low antibody status in this study. This value also corresponds to the 33rd percentile in the first-month antibody results. Descriptive statistics were generated in numbers and percentages for categorical variables. Conformity of continuous variables to normal distribution was examined visually (by means of histograms and probability graphs) and statistically (by means of Kolmogorov-Smirnov/Shapiro-Wilk tests). If continuous variables fit the normal distribution, the mean and standard deviation were calculated, if not, the median and 25th-75th percentile (Interquartile range) were used. Categorical variables were compared using Pearson χ 2 or Fisher's exact tests. Since the quantitative antibody levels were not normally distributed, the Mann-Whitney U test was used for two groups and the Kruskal-Wallis test for more than two groups. The Bonferroni correction was used when the result was statistically significant in the Kruskal Wallis test by employing a pairwise comparison of groups. The Wilcoxon test was used for quantitative antibody level comparison in dependent groups. The antibody levels (low/high) were converted to dichotomous variables. Whether covariates were risk factors for low antibody response was evaluated by univariate and multivariate logistic regression analysis. Then, independent predictors for the outcome variable were determined using the backward elimination method. The Hosmer-Lemeshow test was used for model fit. Analyses were performed using SPSS 22.0 (IBM Corporation), and p < 0.05 was considered statistically significant. A total of 548 healthcare workers participated in the study ( Figure 1 ). The mean age was 38.7 ± 10.3 (min: 20, max: 65). Age, sex, occupation, presence of chronic disease, immunosuppressive-modulatory treatment status, BMI, smoking, vaccination status with influenza, and pneumococcal vaccines are shown in Table 1 . At least one chronic disease was observed in 146 (26.6%) of the participants, and 17 (3.1%) were using immunosuppressive-modulatory treatment. Distribution of chronic diseases was hypertension (n: 60, 32%), asthma-allergy (n: 32, 17.2%), connective tissue disease (n: 25, 13 .4%), diabetes mellitus (n: 24, 12.8%), cardiovascular disease (n: 16, 8 .6%), cancer (remission/active) (n: 12, 6.5%), chronic lung disease (n: 7, 3.7%), chronic kidney disease (n: 5, 2.8%), chronic neurological disease (n: 3, 1.6%), chronic liver disease (n: 2, 1%), and asplenia (n: 1, 0.5%). Thirty-four participants had more than one chronic disease. The first-month evaluation after the second dose of the vaccine showed 98.9% seropositivity, with a median antibody level of 473.6 (251.5-828.6) AU/mL, min: 4, max: 5224.2 AU/ml ( Figure 2 ). There were six seronegative participants (1.1%), four of whom had chronic disease and/or obesity. The first-month antibody levels were found to be significantly higher in the 20-35 age group (vs. 36-50 age group), in physicians (vs. other healthcare professionals), in participants with normal weight (vs. overweight participants), in people who did not have chronic diseases, and did not use immunosuppressive-modulatory therapy ( Although the highest antibody levels were expected in the young individuals in our study, the high antibody levels detected over the age of 50 showed that the inactivated vaccine can produce a good antibody response in the older age groups as well. Different results have been reported regarding the relationship between sex and vaccine response. Although a lower antibody response is frequently reported in males receiving the mRNA BNT162b2 15, 18 or CoronaVac vaccine, 19 no difference was found between the first month antibody levels in males and females, and there was no association between male sex and low antibody levels in this study. In the univariate logistic regression analysis, nurses and other healthcare professionals were in the risk group for low antibody response compared to the physician group, but no difference was found between the occupational groups in the multivariate analysis. Low antibody levels were detected in healthcare workers receiving immunosuppressive therapy. Similar results were reported in other CoronaVac studies. 20,21 Therefore, we suggest a booster dose in immunocompromised individuals. Chronic diseases may also cause a low response to COVID-19 vaccines, but the results of inactivated vaccine studies on this subject are quite different from each other. 14,19 Differences could be due to the type of chronic diseases in the study groups. Obesity is another issue that affects the response to the vaccine, as shown in this study. Pellini et al. 22 reported that higher levels of antibodies were detected with mRNA BNT162b2 vaccine in low-weight and normal-weight individuals compared to pre-obese individuals. In our study, being overweight was found to be a risk factor for low antibody levels in the univariate logistic regression analysis, but it was not found as a predictor when the variables were adjusted simultaneously. In this study, when the responses at the fourth month were compared with the first month ones, antibody levels decreased by 61% and even became seronegative by 10%. In a CoronaVac study, a 56.7% decrease was observed between antibody levels measured at the first and third months after the second dose. 13 A decrease in antibody levels over time after vaccination is also observed with other COVID-19 vaccines. Individuals who were seronegative at baseline and vaccinated with two doses of mRNA BNT162b2 had a mean antibody level reduction of 37.9% at 3 months, although seropositivity persisted in all participants. 23 In another study with the same vaccine, there was a sharp decrease (56.8%) in the antibody results at the fourth month. 24 In an mRNA-1273 vaccine study, when the antibody levels at the third and sixth months after the complete vaccination scheme were compared, there was a significant decrease, especially in the individuals who were seronegative at the beginning. 25 Compared to studies done with other vaccine types, antibody reduction and the percentage of seronegativity were greater with CoronaVac. However, the clinical significance of this reduction should be carefully evaluated. Circulating antibody titers are not necessarily predictive for T cell memory. 26 Six months after two doses of an inactivated vaccine, enzyme-linked immunosorbent assay (ELISA)identified anti-S and anti-N antibodies exhibited a gradual decline although immune memory based on interferon-γ-secreting T cells persisted. 27 There is also evidence showing that higher levels of antibody response were correlated with a reduced risk of symptomatic infection but did not protect from asymptomatic infection. 28 In our study, although a decrease in antibody level was detected in most of the participants, 6% of them had an increase in the fourth month. This may be due to test variability or asymptomatic infection. A systematic review of these studies showed that heterologous administration of BNT162b2 in ChAdOx1-primed participants has robust immunogenicity, higher T cell response, and neutralizing activity against variants of concern. 30 There are some limitations of our study. First, the subjects included in the study were not initially screened serologically, and hence those with asymptomatic infections may have inadvertently been included in the study group. Second, participants with asymptomatic infections during the study may not have been detected because they were not regularly screened by PCR. However, considering the antibody levels, the rate of asymptomatic infection was expected to be low. The third is the possibility of selection bias due to participants being lost to followup. A decrease in the number of participants at the second and third blood draw was observed. The main reason could be assumed as the heavy workload due to the pandemic, as well as that some health workers were working in shifts in our hospital and some were on annual leave during the summer period. In the first and fourth months after the inactivated vaccine scheme, there was a 21% loss in participants. All variables, except sex, were similar between the two groups at 4 months. This may cause a biased estimate of antibody levels but we believe the effect may be small, owing to there being no significant difference in antibody levels between men and women at baseline. CoronaVac is only approved in a small number of countries and is relatively less studied than mRNA or viral vector vaccines. An important strength of this study is that it adds to the limited data in the literature evaluating the short-to-medium term antibody response of the inactivated vaccine. The efficient system that tracks PCR positivity, infection dates, and vaccination status of healthcare workers in our OHSU ensured accurate data collection. The major importance of this study is that it provides novel data about the anti-RBD antibody results of mRNA or inactivated vaccine booster administered after the primary vaccine scheme with CoronaVac is completed. Although the seropositivity rate was quite high with two doses of in- World Health Organization. Coronavirus (COVID-19) dashboard Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial Evidence for antibody as a protective correlate for COVID-19 vaccines Anti-SARS-CoV-2 antibodies testing in recipients of COVID-19 vaccination: why, when, and how? Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel Interim statement on COVID-19 vaccine booster doses FDA authorizes booster dose of Pfizer-BioNTech COVID-19 vaccine for certain populations World Health Organization Reference Panel. First WHO international reference panel for anti-SARS-CoV-2 immunoglubulin NIBSC code: 20/268 instructions for use Humoral immune response in inactivated SARS-CoV-2 vaccine: when should a booster dose be administered? medRxiv Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers Anti-SARS-CoV-2 receptor-binding domain total antibodies response in seropositive and seronegative healthcare workers undergoing COVID-19 mRNA BNT162b2 vaccination Quantitative SARS-CoV-2 antispike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status COVID-19: why we can't use antibody tests to show that vaccines are working Impact of age and sex on antibody response following the second dose of COVID-19 BNT162b2 mRNA vaccine in Greek healthcare workers. Microorganisms Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: prospective observational study Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderly Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial Early onset of SARS-COV-2 antibodies after first dose of BNT162b2: correlation with age, gender and BMI Antibody titres decline 3-month post-vaccination with BNT162b2 HLA does not impact on shortmedium-term antibody response to preventive anti-SARS-Cov-2 vaccine Immunogenicity of mRNA-1273 COVID vaccine after 6 months surveillance in health care workers; a third dose is necessary Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection Intensified antibody response elicited by boost suggests immune memory in individuals administered two doses of SARS-CoV-2 inactivated vaccine Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection A third booster dose may be necessary to mitigate neutralizing antibody fading after inoculation with two doses of an inactivated SARS-CoV-2 vaccine To mix or not to mix? A rapid systematic review of heterologous prime-boost covid-19 vaccination Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen The authors declare no conflict of interest. The raw anonymous participant data will be available immediately following publication and ending 1 year following article publication upon request to the corresponding author. Proposals will be reviewed and approved by the researchers on the basis of scientific merit. Once the proposal has been approved, data can be transferred through a secure online platform after signing a data access agreement and a confidentiality agreement. http://orcid.org/0000-0002-9088-5097